Kennedy Capital Management’s Editas Medicine EDIT Stock Holding History

Kennedy Capital Management’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.34M	Sell	1,032,133 -20,324	-2%	-$59.4K	0.06%	384
2026 Q1	$2.6M	Buy	1,052,457 +490,317	+87%	+$1.04M	0.06%	394
2025 Q4	$1.15M	Sell	562,140 -3,501	-0.6%	-$10.1K	0.02%	469
2025 Q3	$1.96M	Sell	565,641 -1,978	-0.3%	-$5.52K	0.04%	450
2025 Q2	$1.25M	Buy	567,619 +40,879	+8%	+$66.9K	0.03%	484
2025 Q1	$611K	Sell	526,740 -2,096	-0.4%	-$3.08K	0.01%	570
2024 Q4	$672K	Sell	528,836 -11,299	-2%	-$28.8K	0.01%	625
2024 Q3	$1.84M	Buy	540,135 +407,487	+307%	+$1.77M	0.04%	527
2024 Q2	$619K	Sell	132,648 -566	-0.4%	-$3.19K	0.01%	628
2024 Q1	$988K	Buy	+133,214	New	+$1.11M	0.02%	621

Other funds holding EDIT

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Kennedy Capital Management's EDIT Position: Q2 2026 in Review

Kennedy Capital Management reduced its Editas Medicine (EDIT) stake by 1.9% in Q2 2026, selling an estimated $59.4K and leaving 1,032,133 shares worth $3.34M. The position accounts for 0.06% of the portfolio, ranked #384.

Kennedy Capital Management first reported a position in EDIT in Q1 2024 and has held it in 10 quarters since. 216 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

Kennedy Capital Management held 1,032,133 shares of Editas Medicine worth $3.34M as of Q2 2026.
Kennedy Capital Management sold 20,324 Editas Medicine shares in Q2 2026, an estimated $59.4K.
Editas Medicine made up 0.06% of Kennedy Capital Management's portfolio in Q2 2026, its #384 holding.
Kennedy Capital Management first reported a position in Editas Medicine in Q1 2024 and has held it in 10 quarters since.
216 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.